R&D Pipeline

 

Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of autoimmune disorders, chronic inflammatory conditions and cancer.

Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.

Therapeutic Area
Condition/Disease
Agents
Mechanism
Phase
Partner
Hematological Cancer
Large B-Cell Lymphoma
NKTR-255 + Yescarta® or Breyanzi® 
Phase 2/3
Agent(s) NKTR-255 + Yescarta® or Breyanzi® 
+
Solid Tumors
Maintenance Bladder Cancer
NKTR-255 + Bavencio®
Phase 2
Agent(s) NKTR-255 + Bavencio®
+
Solid Tumors
Stage 2 Non-small Cell Lung Cancer Post Chemoradiation
NKTR-255 + Imfinzi®
Phase 1/2
Agent(s) NKTR-255 + Imfinzi®
+
Hematological Cancer
Relapsed/Refractory Large B Cell Lymphoma
NKTR-255 + Breyanzi®
Phase 1
+
Hematological Cancer
B-Cell Acute Lymphoblastic Leukemia
NKTR-255 + CD19/22.BB.z-CAR-T Cell
Phase 1
Agent(s) NKTR-255 + CD19/22.BB.z-CAR-T Cell
+
Autoimmune Disorders
Atopic Dermatitis
REZPEG (NKTR-358)
Phase 1B
Agent(s) REZPEG (NKTR-358)
+
Autoimmune Disorders
TNFR antibody
Preclinical
Agent(s) TNFR antibody
+
Immuno-Oncology
NKTR-288
Preclinical
Agent(s) NKTR-288
+